In 2024, the FDA approved 57 new therapeutic drugs, slightly above the decade average but well below the 2023 record of 71, with projected peak sales of $60 billion—significantly lower than past averages due to the absence of mega-blockbusters. Looking ahead, scientific advancements, AI-driven drug discovery, and novel therapeutic approaches drive optimism, but industry challenges such as competitive pressures, targeted therapies for smaller populations, and drug pricing scrutiny remain key factors to watch.